Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Multivariate-adjusted Cox proportional hazard regression models predicting OS and RFS classified by AJCC 8th edition N stage, LNR, and LODDS

From: Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment

  Number of patients OS RFS
Median OS, months HR (95% CI) a p AIC Bootstrap-corrected C index Median RFS, months HR (95% CI) a p AIC Bootstrap-corrected C index
pN (AJCC 8th)
 0 150 50.8 1 < 0.001 2003.0 0.57 23.5 1 < 0.001 2274.3 0.57
 1 135 27.0 1.58 (1.14-2.19) 15.0 1.34 (0.98-1.83)
 2 66 22.5 2.00 (1.36-2.95) 10.1 2.01 (1.38-2.92)
LNR
 0 150 50.8 1 < 0.001 2005.9 0.65 23.5 1 0.001 2278.4 0.63
  > 0 to ≤0.2 141 26.3 1.62 (1.17-2.23) 13.5 1.39 (1.02-1.88)
  > 0.2 to ≤0.4 23 21.5 1.66 (0.90-3.01) 11.0 1.80 (1.02-3.18)
  > 0.4 37 21.4 2.05 (1.31-3.20) 9.2 1.90 (1.23-2.96)
LODDS
 Quantile 1 89 48.8 1 0.002 2008.8 0.64 20.6 1 0.009 2277.5 0.63
 Quantile 2 91 34.8 1.26 (0.84-1.91) 17.3 1.17 (0.79-1.72)
 Quantile 3 85 27.4 1.46 (0.97-2.20) 15.4 1.24 (0.84-1.84)
 Quantile 4 86 22.0 1.90 (1.25-2.87) 10.1 1.78 (1.21-2.62)
  1. OS overall survival, RFS recurrence-free survival, AIC akaike information criterion, AJCC American Joint Committee on Cancer, LNR lymph-node ratio, LODDS log odds of positive lymph nodes, CA 19-9 carbohydrate antigen 19-9
  2. a HR adjusted with the histologic grade, lymphovascular invasion, perineural invasion, pathologic T stage, and preoperative CA19-9 ≥ 100 U/mL